Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AVN-944 capsules for oral administration
AVN-944 for administration · 1 trial · 6 indications
| Name | Type | Description |
|---|---|---|
| AVN-944 capsules for oral administration | DRUG | - |
Inclusion Criteria: 1. Histologically or cytologically confirmed chronic myelogenous leukemia, acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, non-Hodgkin's lymphoma or Hodgkin's disease. 2. Patients must be refractory to, intolerant of, or dec...
AVN-944 is an investigational small molecule being studied in acute leukemia and other advanced hematologic malignancies. It was developed by Vertex Pharmaceuticals and has been evaluated in a Phase 1 trial in patients with blood cancers, including acute leukemia, chronic leukemia, multiple myeloma, and lymphomas.
AVN-944 targets IMPDH1 and IMPDH2, two isoforms of inosine monophosphate dehydrogenase. It acts as an inhibitor of these enzymes, which are involved in guanine nucleotide synthesis. This mechanism is intended to interfere with the proliferation of hematologic cancer cells.
AVN-944 was developed by Vertex Pharmaceuticals Incorporated, which trades on the Nasdaq under the ticker VRTX. Vertex is a biopharmaceutical company focused on discovering and developing small molecule drugs for serious diseases.
AVN-944 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The only reported trial was a completed Phase 1 study in patients with advanced hematologic malignancies.
AVN-944 has been studied in one completed Phase 1 trial, NCT00273936, titled "Trial of AVN-944 in Patients With Advanced Hematologic Malignancies." The trial enrolled 72 patients in the United States and included conditions such as acute leukemia, chronic leukemia, multiple myeloma, and lymphomas.
Yes, AVN-944 capsules for oral administration is another name for AVN-944. The drug is formulated as oral capsules, and both names refer to the same investigational small molecule developed by Vertex Pharmaceuticals.